Top

Published in:

01-06-2016 | Literatur kommentiert

Alleinige IF-RT bleibt Goldstandard beim nodulären lymphozytenprädominanten Hodgkin-Lymphom im Stadium IA

Authors: Karoline Pilz, Dr. Christina Jentsch, Prof. Dr. Mechthild Krause

Published in: Strahlentherapie und Onkologie | Issue 6/2016

Auszug

Eine optimale Therapie des nodulären lymphozytenprädominanten Hodgkin-Lymphoms (NLPHL) ist im Stadium IA bisher nicht ausreichend definiert. Aus diesem Grund wurde eine Datenanalyse in der Datenbank der Deutschen Hodgkin-Studiengruppe durchgeführt. …

Diehl V, Sextro M, Franklin J et al (1999) Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin’s Disease. J Clin Oncol 17:776–783PubMed

Anagnostopoulos I, Hansmann ML, Franssila K et al (2000) European task force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 96:1889–1899PubMed

Nogová L, Reineke T, Brillant C et al (2008) Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 26:434–439. doi:10.1200/JCO.2007.11.8869CrossRefPubMed

Pappa VI, Norton AJ, Gupta RK et al (1995) Nodular type of lymphocyte predominant Hodgkin’s disease. A clinical study of 50 cases. Ann Oncol 6:559–565PubMed

Trudel MA, Krikorian JG, Neiman RS (1987) Lymphocyte predominance Hodgkin’s disease. A clinicopathologic reassessment. Cancer 59:99–106CrossRefPubMed

Rehwald U, Schulz H, Reiser M et al (2003) Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 101:420–424. doi:10.1182/blood.V101.2.420CrossRefPubMed

Ekstrand BC, Lucas JB, Horwitz SM et al (2003) Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 101:4285–4289. doi:10.1182/blood-2002-08-2644CrossRefPubMed

Nogová L, Reineke T, Eich HT et al (2005) Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 16:1683–1687. doi:10.1093/annonc/mdi323CrossRefPubMed

Hoppe RT, Advani RH, Ai WZ et al (2012) Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Cancer Netw 10:589–597

10.

Wilder RB, Schlembach PJ, Jones D et al (2002) European organization for research and treatment of cancer and Groupe d’etude des Lymphomes de l’Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer 94:1731–1738CrossRefPubMed

11.

Wirth A, Yuen K, Barton M et al (2005) Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer 104:1221–1229. doi:10.1002/cncr.21303CrossRefPubMed

12.

Nicholas DS, Harris S, Wright DH (1990) Lymphocyte predominance Hodgkin’s disease – an immunohistochemical study. Histopathology 16:157–165CrossRefPubMed

13.

Eichenauer DA, Plütschow A, Fuchs M et al (2015) Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin Lymphoma: A report from the german Hodgkin study group. J Clin Oncol 33:2857–2862. doi:10.1200/JCO.2014.60.4363CrossRefPubMed

14.

Schlembach PJ, Wilder RB, Jones D et al (2002) Radiotherapy alone for lymphocyte-predominant Hodgkin’s disease. Cancer J 8:377–383CrossRefPubMed

15.

Cosset JM, Henry-Amar M, Meerwaldt JH (1991) Long-term toxicity of early stages of Hodgkin’s disease therapy: the EORTC experience. EORTC Lymphoma Cooperative Group. Ann Oncol 2(Suppl 2):77–82CrossRefPubMed

16.

Koh E‑S, Tran TH, Heydarian M et al (2007) A comparison of mantle versus involved-field radiotherapy for Hodgkin’s lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol 2:13 doi:10.1186/1748-717X-2-13CrossRefPubMedPubMedCentral

17.

Hodgson DC, Koh E‑S, Tran TH et al (2007) Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 110:2576–2586. doi:10.1002/cncr.23081CrossRefPubMed

Title: Alleinige IF-RT bleibt Goldstandard beim nodulären lymphozytenprädominanten Hodgkin-Lymphom im Stadium IA
Authors: Karoline Pilz
Dr. Christina Jentsch
Prof. Dr. Mechthild Krause
Publication date: 01-06-2016
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 6/2016
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-016-0975-y

At a glance: The STEP trials

Springer Medicine

Alleinige IF-RT bleibt Goldstandard beim nodulären lymphozytenprädominanten Hodgkin-Lymphom im Stadium IA

Auszug

At a glance: The STEP trials

Springer Medicine

Auszug

Please log in to get access to this content

Other articles of this Issue 6/2016

IMRT-Expertise des Radioonkologen und Prognose bei Kopf-Hals-Tumoren

EGFR-Inhibition bei NSCLC-Tumorzelllinien

HFSRT of the resection cavity in patients with brain metastases

Iterative metal artifact reduction improves dose calculation accuracy

IMRT vs. 2D-radiotherapy or 3D-conformal radiotherapy of nasopharyngeal carcinoma

Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma